Huahui Health Partners with BeOne Medicines for Groundbreaking Cancer Immunotherapy

Huahui Health has announced a global agreement with BeOne Medicines for HH160, a novel trispecific antibody in cancer immunotherapy. BeOne will pay Huahui Health a USD 20 million upfront fee and USD 100 million upon option exercise, with potential milestone payments up to USD 1.9 billion and tiered sales royalties.

Huahui Health has entered a significant collaboration agreement with BeOne Medicines for the development and commercialization of HH160, a novel trispecific antibody designed for oncology immunotherapy. The collaboration grants BeOne Medicines an exclusive option to develop, manufacture, and commercialize HH160 worldwide.

Under the terms of the agreement, BeOne Medicines will make an upfront payment of USD 20 million to Huahui Health, and an additional payment of USD 100 million upon exercising the option. Furthermore, Huahui Health may receive up to USD 1.9 billion in milestone payments, along with tiered royalties on net sales of HH160.

HH160, created using Huahui Health’s proprietary PolyBoost™ platform, targets PD-1, CTLA-4, and VEGF-A, offering a unique 'three-in-one' approach to cancer treatment, aimed at enhancing therapeutic efficacy and reducing adverse treatment effects. The agreement marks a landmark moment in the potential revolutionizing of cancer therapies worldwide.